白介素-2治疗自身免疫性肝炎疗效研究进展与展望*

doi:10.3969/j.issn.1672-5069.2025.03.003

Abstract

Luo Yuexin, Luo Hongchun. Interleukin-2 in the treatment of patients with autoimmune hepatitis: current state of the art, controversies, and perspectives[J]. Journal of Practical Hepatology, 2025, 28(3): 330-333.

References

[1] 中华医学会肝病学分会. 自身免疫性肝炎诊断和治疗指南(2021年). 临床肝胆病杂志, 2022, 38(1): 42-49.
[2] Taubert R, Hardtke-Wolenski M, Noyan F, et al. Intrahepatic regulatory T cells in autoimmune hepatitis are associated with treatment response and depleted with current therapies. J Hepatol,2014, 61(5): 1106-1114.
[3] Malek TR. The biology of interleukin-2. Annu Rev Immunol, 2008, 26: 453-479.
[4] Denny P, Lord CJ, Hill NJ, et al. Mapping of the IDDM locus Idd3 to a 0.35-cM interval containing the interleukin-2 gene. Diabetes, 1997, 46(4): 695-700.
[5] Kane LP, Lin J, Weiss A. It's all relative: NF-kappaB and CD28 costimulation of T-cell activation. Trends Immunol, 2002, 23(8): 413-420.
[6] Isakov N, Altman A. Protein kinase C(theta) in T cell activation. Annu Rev Immunol, 2002, 20: 761-794.
[7] Ho IC, Kim JI, Szabo SJ, et al. Tissue-specific regulation of cytokine gene expression. Cold Spring Harb Symp Quant Biol, 1999, 64: 573-584.
[8] Rickert M, Wang X, Boulanger MJ, et al. The structure of interleukin-2 complexed with its alpha receptor. Science, 2005, 308(5727): 1477-1480.
[9] Takeshita T, Asao H, Ohtani K, et al. Cloning of the gamma chain of the human IL-2 receptor. Science, 1992, 257(5068): 379-382.
[10] Smith GA, Taunton J, Weiss A. IL-2Rβ abundance differentially tunes IL-2 signaling dynamics in CD4(+) and CD8(+) T cells. Sci Signal, 2017, 10(510).
[11] Wang X, Rickert M, Garcia KC. Structure of the quaternary complex of interleukin-2 with its alpha, beta, and gammac receptors. Science, 2005, 310(5751): 1159-1163.
[12] Fontenot JD, Rasmussen JP, Gavin MA, et al. A function for interleukin 2 in Foxp3-expressing regulatory T cells. Nat Immunol, 2005, 6(11): 1142-1151.
[13] Boyman O, Sprent J. The role of interleukin-2 during homeostasis and activation of the immune system. Nat Rev Immunol, 2012, 12(3): 180-190.
[14] Goudy K, Aydin D, Barzaghi F, et al. Human IL2RA null mutation mediates immunodeficiency with lymphoproliferation and autoimmunity. Clin Immunol, 2013, 146(3): 248-261.
[15] Sakaguchi S, Sakaguchi N, Asano M, et al. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol, 1995, 155(3): 1151-1164.
[16] Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science, 2003, 299(5609): 1057-1061.
[17] Miyara M, Gorochov G, Ehrenstein M, et al. Human FoxP3+ regulatory T cells in systemic autoimmune diseases. Autoimmun Rev, 2011, 10(12): 744-755.
[18] Longhi MS, Ma Y, Mitry RR, et al. Effect of CD4⁺ CD25⁺ regulatory T-cells on CD8 T-cell function in patients with autoimmune hepatitis. J Autoimmun, 2005, 25(1): 63-71.
[19] Longhi MS, Ma Y, Bogdanos DP, et al. Impairment of CD4(+)CD25(+) regulatory T-cells in autoimmune liver disease. J Hepatol, 2004, 41(1): 31-37.
[20] Dominguez-Villar M, Hafler DA. Regulatory T cells in autoimmune disease. Nat Immunol, 2018, 19(7): 665-673.
[21] Abbas AK, Trotta E, D RS, et al. Revisiting IL-2: Biology and therapeutic prospects. Sci Immunol, 2018, 3(25):1213-1217.
[22] Morgan DA, Ruscetti FW, Gallo R. Selective in vitro growth of T lymphocytes from normal human bone marrows. Science, 1976, 193(4257): 1007-1008.
[23] Miyazaki T, Liu ZJ, Kawahara A, et al. Three distinct IL-2 signaling pathways mediated by bcl-2, c-myc, and lck cooperate in hematopoietic cell proliferation. Cell, 1995, 81(2): 223-231.
[24] Josefowicz SZ, Lu LF, Rudensky AY. Regulatory T cells: mechanisms of differentiation and function. Annu Rev Immunol, 2012, 30: 531-564.
[25] Busse D, de la Rosa M, Hobiger K, et al. Competing feedback loops shape IL-2 signaling between helper and regulatory T lymphocytes in cellular microenvironments. Proc Nat Acad Sci, 2010, 107(7): 3058-3063.
[26] Chinen T, Kannan AK, Levine AG, et al. An essential role for the IL-2 receptor in T(reg) cell function. Nat Immunol, 2016, 17(11): 1322-1333.
[27] Barron L, Dooms H, Hoyer KK, et al. Cutting edge: mechanisms of IL-2-dependent maintenance of functional regulatory T cells. J Immunol, 2010, 185(11): 6426-6430.
[28] Leonard WJ, Lin JX. Strategies to therapeutically modulate cytokine action. Nat Rev Drug Discov, 2023, 22(10): 827-854.
[29] Saadoun D, Rosenzwajg M, Joly F, et al. Regulatory T-cell responses to low-dose interleukin-2 in HCV-induced vasculitis. N Engl J Med, 2011, 365(22): 2067-2077.
[30] Yu A, Snowhite I, Vendrame F, et al. Selective IL-2 responsiveness of regulatory T cells through multiple intrinsic mechanisms supports the use of low-dose IL-2 therapy in type 1 diabetes. Diabetes, 2015, 64(6): 2172-2183.
[31] Rosenzwajg M, Lorenzon R, Cacoub P, et al. Immunological and clinical effects of low-dose interleukin-2 across 11 autoimmune diseases in a single, open clinical trial. Ann Rheum Dis, 2019, 78(2): 209-217.
[32] Kim S, Maeng JY, Hyun SJ, et al. Extracellular vesicles from human umbilical cord blood plasma modulate interleukin-2 signaling of T cells to ameliorate experimental autoimmune encephalomyelitis. Theranostics, 2020, 10(11): 5011-5028.
[33] Klatzmann D, Abbas AK. The promise of low-dose interleukin-2 therapy for autoimmune and inflammatory diseases. Nat Rev Immunol, 2015, 15(5): 283-294.
[34] Arenas-Ramirez N, Woytschak J, Boyman O. Interleukin-2: Biology, design and application. Trends Immunol, 2015, 36(12): 763-777.
[35] Boyman O, Kovar M, Rubinstein MP, et al. Selective stimulation of T cell subsets with antibody-cytokine immune complexes. Science, 2006, 311(5769): 1924-1927.
[36] Buitrago-Molina LE, Pietrek J, Noyan F, et al. Treg-specific IL-2 therapy can reestablish intrahepatic immune regulation in autoimmune hepatitis. J Autoimmun, 2021, 117: 102591.
[37] Spangler JB, Tomala J, Luca VC, et al. Antibodies to interleukin-2 elicit selective T cell subset potentiation through distinct conformational mechanisms. Immunity, 2015, 42(5): 815-825.
[38] Trotta E, Bessette PH, Silveria SL, et al. A human anti-IL-2 antibody that potentiates regulatory T cells by a structure-based mechanism. Nat Med, 2018, 24(7): 1005-1014.
[39] Tchao N, Gorski KS, Yuraszeck T, et al. Amg 592 is an investigational IL-2 mutein that induces highly selective expansion of regulatory T cells. Blood, 2017, 130(Supplement 1): 696-696.
[40] Gorski KS, Stern J, Hsu Y-H, et al. THU0031 phenotype of foxp3⁺ regulatory T-cells expanded by the il-2 mutein, amg 592 in healthy subjects in phase 1, first-in-human study. Ann Rheumat Dis, 2018, 77(Suppl 2): 243-243.
[41] Peterson LB, Bell CJM, Howlett SK, et al. A long-lived IL-2 mutein that selectively activates and expands regulatory T cells as a therapy for autoimmune disease. J Autoimmun, 2018, 95: 1-14.
[42] Hsieh YT, Hubeau C, Massa V, et al. OP0316 emerging best-in-class IL-2 variant highlights TREG-directed therapy for autoimmune disease. Ann Rheumat Dis, 2020, 79(Suppl 1): 195-195.
[43] Khoryati L, Pham MN, Sherve M, et al. An IL-2 mutein engineered to promote expansion of regulatory T cells arrests ongoing autoimmunity in mice. Sci Immunol, 2020, 5(50):329-334.
[44] Zhang B, Sun J, Wang Y, et al. Site-specific PEGylation of interleukin-2 enhances immunosuppression via the sustained activation of regulatory T cells. Nat Biomed Eng, 2021, 5(11): 1288-1305.
[45] Ottolenghi A, Bolel P, Sarkar R, et al. Life-extended glycosylated IL-2 promotes Treg induction and suppression of autoimmunity. Sci Rep, 2021, 11(1): 7676.

Interleukin-2 in the treatment of patients with autoimmune hepatitis: current state of the art, controversies, and perspectives

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Kong Lixia, Chen Xufeng, Xu Yan, et al. Sequential or combined rescue antiviral therapy by tenofovir amibufenamide in entecavir-treated chronic hepatitis B patients with low-level viremia [J]. Journal of Practical Hepatology, 2025, 28(3): 334-337.
[2]	Wang Hao, Wang Qingyuan, Shen Qiong, et al. Satisfactory response to pegylated interferon α-2a and albavir/granrivir combination therapy in patients with chronic hepatitis C [J]. Journal of Practical Hepatology, 2025, 28(3): 346-349.
[3]	Xu Lingling, Lu Yuan, Zheng Yanchai, et al. Improvement of liver function tests by oral bicyclol in patients with type 2 diabetes mellitus and nonalcoholic steatohepatitis [J]. Journal of Practical Hepatology, 2025, 28(3): 358-361.
[4]	Wen Dachao, Zhang Qiuping, Shi Ling. Short-term observation of acupoint application and exercise in the treatment of patients with non-alcoholic fatty liver disease [J]. Journal of Practical Hepatology, 2025, 28(3): 370-373.
[5]	Ma Dantong, Yang Shuang, Gao Lili, et al. Clinical feature of patients with drug-induced autoimmune-like hepatitis: An analysis of 73 cases [J]. Journal of Practical Hepatology, 2025, 28(3): 390-393.
[6]	Li Yongfei, Xu Zhengju, Ye Qiaoxia, et al. Efficacy of plasma exchange and hemofiltration in the treatment of patients with acute-on-chronic hepatitis B liver failure [J]. Journal of Practical Hepatology, 2025, 28(3): 394-397.
[7]	Xu Rongbo, Wang Yan, Wang Xiaosong, et al. Efficacy of endoscopic variceal ligation and somatostatin and esomeprazole combination in the treatment of patients with liver cirrhosis with complicated esophagogastric variceal bleeding [J]. Journal of Practical Hepatology, 2025, 28(3): 410-413.
[8]	Jiang Zhaoqin, Song Jie, Mu Yongfang. Efficacy of endoscopic variceal ligation with combination of intravenous administration of somatostatin and omeprazole in the treatment of liver cirrhosis patients with esophagogastric variceal bleeding [J]. Journal of Practical Hepatology, 2025, 28(3): 422-425.
[9]	Yang Yijin, Hong Han, Chen Bin, et al. FOLFOX in hepatic artery infusion chemotherapy with combination of lenvatinib and PD-1 inhibitors in treatment of patients with advanced primary liver cancer [J]. Journal of Practical Hepatology, 2025, 28(3): 426-429.
[10]	Li Hongjian, Xu Zhiwen, Xia Fei, et al. Intrapurulent catheter drainage under ultrasound guidance in the treatment of patients with bacterial liver abscess [J]. Journal of Practical Hepatology, 2025, 28(3): 454-457.
[11]	Yan Huajun, Chen Xingyun, Ma Bing, et al. Ultrasound-guided percutaneous transhepatic gallbladder puncture drainage and subsequent selective laparoscopic cholecystectomy in treatment of patients with acute calculous obstructive cholecystitis [J]. Journal of Practical Hepatology, 2025, 28(3): 458-461.
[12]	Feng Song, Li lianjie, Cheng Bo. Percutaneous transhepatic gallbladder drainage and sequential laparoscopic cholecystectomy with preservation of main cystic artery in the treatment of patients with acute cholecystitis [J]. Journal of Practical Hepatology, 2025, 28(3): 462-465.
[13]	Ke Junjie, Xing Jieyu, Zhang Mingying. Comparison of endoscopic retrograde cholangiopancreatography and laparoscopic choledochotomy and exploration in the treatment of patients with post-cholecystectomy choledocholithiasis [J]. Journal of Practical Hepatology, 2025, 28(3): 466-469.
[14]	Lyu Tianfu, Nan Qiong. Anticoagulant therapy in patients with cirrhotic portal hypertension after transjugular intrahepatic porto-systemic shunt [J]. Journal of Practical Hepatology, 2025, 28(2): 165-168.
[15]	Qian Hua, Yang Zhongxiang, Shi Li. Influencing factors of low level viremia in patients with chronic hepatitis B during nucleos(t)ide analogue treatment [J]. Journal of Practical Hepatology, 2025, 28(2): 186-189.